Drugs

, Volume 68, Issue 18, pp 2709–2737 | Cite as

Teriparatide

A Review of its Use in Osteoporosis
  • Stephanie K. A. Blick
  • Sohita Dhillon
  • Susan J. Keam
Adis Drug Evaluation

Summary

Abstract

Recombinant teriparatide (Forteo™; Forsteo™) is an anabolic (bone forming) agent. Studies have shown that subcutaneous teriparatide 20 μg/day is effective in women with postmenopausal osteoporosis, men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid-induced osteoporosis. Teriparatide improves bone mineral density (BMD) and alters the levels of bone formation and resorption markers; histomorphometric studies showed teriparatide-induced effects on bone structure, strength and quality.

Subcutaneous teriparatide 20 μg/day administered over a treatment period of 11–21 months was effective in reducing the risk of fractures in and in improving BMD in men with idiopathic or hypogonadal osteoporosis, women with postmenopausal osteoporosis and patients with glucocorticoid-induced osteoporosis. Furthermore, the beneficial effects of teriparatide on vertebral fracture prevention and BMD appear to persist following treatment cessation. Teriparatide is generally well tolerated and treatment compliance rates are favourable. However, current limitations on the length of treatment and the high acquisition cost mean that teriparatide is best reserved for the treatment of patients with osteoporosis at high risk of fracture, or for patients with osteoporosis who have unsatisfactory responses to or intolerance of other osteoporosis therapies.

Pharmacological Properties

Teriparatide is the 1-34 N-terminal fragment of human parathyroid hormone (PTH) and appears to contain all the anabolic properties of the full-length PTH. Both teriparatide and endogenous PTH mediate their biological effects via specific, high-affinity membrane cell-surface receptors expressed on osteoblasts and renal tubular cells. Both molecules bind to the receptors with the same affinity and exert the same physiological effects on bone and kidney. Unlike antiresorptive agents (e.g. bisphosphonates and raloxifene) that inhibit bone resorption and preserve existing bone architecture, teriparatide stimulates osteoblastic activity and new bone tissue formation. Increases in levels of bone formation markers occur earlier than increases in bone resorption markers, creating the‘anabolic window’. The early changes in biochemical markers of bone formation may correlate with improvements in bone structure and BMD. The effects of teriparatide on calcium and phosphorous metabolism are consistent with those seen with endogenous PTH (transient increase in serum calcium and decrease in serum phosphate).

Subcutaneous teriparatide is rapidly and extensively absorbed and has an absolute bioavailability of 95%. Peak serum concentration was achieved ≈30 minutes after administration of subcutaneous teriparatide 20 μg in healthy volunteers and in postmenopausal women with osteoporosis, after which time concentrations declined to nonquantifiable levels within 3 hours. Teriparatide is not expected to accumulate in bone. Subcutaneous teriparatide has a half-life of ≈1 hour, which reflects the time required for absorption from the injection site. It is eliminated via hepatic and extra-hepatic clearance. No metabolism or excretion studies have been undertaken for teriparatide; however, it is believed that peripheral metabolism of endogenous parathyroid hormone occurs largely in the liver, followed by excretion via the kidneys. In the EU, teriparatide is not recommended for use in patients with severe renal impairment.

Therapeutic Efficacy

In large, well designed clinical trials, teriparatide was effective in reducing fracture risk, increasing BMD values (particularly at the lumbar spine) and increasing bone turnover marker levels in male idiopathic or hypogonadal osteoporosis, and in postmenopausal and glucocorticoid-induced osteoporosis.

In a large, pivotal, placebo-controlled, double-blind clinical trial in women with postmenopausal osteoporosis, subcutaneous teriparatide 20 μg/day over a median of 21 months’ duration effectively reduced vertebral and nonvertebral fracture risk (but not hip fractures), and increased markers of bone formation over markers of bone resorption leading to increases in lumbar spine, femoral neck and total hip BMD. Significantly fewer recipients of teriparatide 20 μg/day than placebo had at least one new vertebral fracture (5% vs 14%; relative risk reduction of 65%). Subgroup analyses of data from this trial showed that teriparatide was effective in women with varying degrees of disease severity, and that efficacy was independent of age, renal function, pretreatment BMD values, or the number or severity of prior vertebral fractures.

Teriparatide 20 μg/day was more effective in increasing lumbar spine BMD values after 6–24 months’ treatment in women with postmenopausal osteoporosis than the antiresorptive comparators, alendronate or calcitonin. Both teriparatide and alendronate had positive effects on BMD, but these were significantly greater with teriparatide than with alendronate.

When teriparatide was combined with raloxifene in postmenopausal women, the teriparatide-mediated effect on bone resorption appeared to be attenuated, with a net effect of increasing bone formation. After 6 months’ treatment, the increase in cross-linked C-telopeptide of type I collagen, a bone resorption marker, was significantly smaller with raloxifene plus teriparatide than the increase observed with teriparatide monotherapy. However, when teriparatide was added to an existing alendronate or raloxifene regimen, significant increases from baseline were observed in lumbar spine and total hip BMD, but overall, coadministration did not appear to enhance the activity of either agent as monotherapy.

Switching to teriparatide after antiresorptive therapy in postmenopausal women results in further increases in BMD. Similarly, on cessation of teriparatide, administration of an antiresorptive capitalizes on teriparatide-induced increases in BMD.

Teriparatide 20 μg/day was more effective than placebo in increasing lumbar spine (primary endpoint) and femoral neck BMD, but not total hip BMD, after a median of 11 months’ treatment in men with either idiopathic or hypogonadal osteoporosis.

In patients with glucocorticoid-induced osteoporosis, teriparatide 20 μg/day over 18 months was more effective in increasing lumbar spine BMD than alendronate. Bone formation marker levels were also significantly increased with teriparatide, but were significantly decreased with alendronate. Significantly fewer vertebral fractures occurred in teriparatide recipients than in alendronate recipients.

Pharmacoeconomic analyses suggest that teriparatide is only cost effective in postmenopausal women with severe osteoporosis and is dominated by alendronate in all other scenarios.

Tolerability

Subcutaneous teriparatide 20 μg/day was generally well tolerated during clinical trials of a median of 21 months’ duration in patients with osteoporosis. The adverse events most commonly reported in teriparatide recipients were pain in limb, nausea, headache and dizziness. Serious adverse events were uncommon, were not significantly different between groups receiving teriparatide and comparator agents and were mostly deemed to be unrelated to study drugs.

There were no reports of osteosarcoma during clinical trials (follow-up <2 years) and the incidence of other malignancies did not differ between teriparatide and placebo recipients. The US prescribing information contains a black box warning regarding the increased incidence of osteosarcoma associated with teriparatide treatment. Since commercial launch of teriparatide in 2002, one case of osteosarcoma in a teriparatide-treated patient has been reported; however, causality between teriparatide and the osteosarcoma could not be established.

Increases in alkaline phosphatase levels have been reported infrequently with teriparatide therapy. Teriparatide is contraindicated in the EU and the US in patients with unexplained elevations of alkaline phosphatase as this may indicate Paget’s disease of bone.

References

  1. 1.
    World Health Organization. Prevention and management of osteoporosis: report of a WHO scientific group. WHO technical report series [online]. Available from URL: http://whqlibdoc.who.int/trs/WHOTRS_921.pdf [Accessed 2008 May 1]
  2. 2.
    European Medicines Agency. Scientific discussion [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/forsteo/659802en6.pdf [Accessed 2008 Apr 3]
  3. 3.
    Francis RM, Aspray TJ, Hide G, et al. Back pain in osteoporotic vertebral fractures. Osteoporos Int 2008; 19(7): 895–903PubMedCrossRefGoogle Scholar
  4. 4.
    Lane JM, Serota AC, Raphael B. Osteoporosis: differences and similarities in male and female patients. Orthop Clin North Am 2006 Oct; 37(4): 601–9PubMedCrossRefGoogle Scholar
  5. 5.
    Summey BT, Yosipovitch G. Glucocorticoid-induced bone loss in dermatologic patients: an update. Arch Dermatol 2006 Jan; 142(1): 82–90PubMedCrossRefGoogle Scholar
  6. 6.
    Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007 Nov 15; 357(20): 2028–39PubMedCrossRefGoogle Scholar
  7. 7.
    Audran M. Drug combination strategies for osteoporosis. Joint Bone Spine 2006 Jul; 73(4): 374–8PubMedCrossRefGoogle Scholar
  8. 8.
    Pfeilschifter J. 2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines. Exp Clin Endocrinol Diabetes 2006 Nov; 114(10): 611–22PubMedGoogle Scholar
  9. 9.
    Moen MD, Scott LJ. Recombinant full-length parathyroid hormone (1–84). Drugs 2006; 66(18): 2371–81PubMedCrossRefGoogle Scholar
  10. 10.
    European Medicines Agency. Teriparatide (Forsteo) 20 μg/80 μL: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/forsteo/H-425-PI-en.pdf[Accessed 2008 Apr 29]
  11. 11.
    Eli Lilly and Company. Forteo™ [teriparatide (rDNA origin)] injection: medical review(s) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2002/21-318_FORTEO_Prntlbl.pdf [Accessed 2008 Jul 3]
  12. 12.
    Eli Lilly. Forteo™ teriparatide (rDNA) injection 750 μg/3 mL [online]. Available from URL: http://www.fda.gov/cder/foi/label/2008/021318s0151bl.pdf [Accessed 2008 Apr 3]
  13. 13.
    Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26(5): 688–703PubMedCrossRefGoogle Scholar
  14. 14.
    Brixen KT, Christensen PM, Ejersted C, et al. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol 2004; 94(6): 260–70PubMedGoogle Scholar
  15. 15.
    Stroup J, Kane MP, Abu-Baker AM. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 2008 Mar 15; 65(6): 532–9PubMedCrossRefGoogle Scholar
  16. 16.
    Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endo Metab Dis 2006; 7(1–2): 113–21Google Scholar
  17. 17.
    Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 May 10; 344(19): 1434–41PubMedCrossRefGoogle Scholar
  18. 18.
    Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18(1): 9–17PubMedCrossRefGoogle Scholar
  19. 19.
    Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005 Nov; 20(11): 1905–11PubMedCrossRefGoogle Scholar
  20. 20.
    Miller PD, Bilezikian JP, Diaz-Curiel M, et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 2007 Sep; 92(9): 3535–41PubMedCrossRefGoogle Scholar
  21. 21.
    Center for Drug Evaluation and Research. Medical review(s) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2002/21-318_FORTEO_Medr_P1.pdf [Accessed 2008 Apr 14]
  22. 22.
    Wermers RA, Recknor CP, Cosman F, et al. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int 2008; 19(7): 1055–65PubMedCrossRefGoogle Scholar
  23. 23.
    Lindsay R, Nieves J, Henneman E, et al. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): Kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993; 77(6): 1535–9PubMedCrossRefGoogle Scholar
  24. 24.
    Cosman F, Dawson-Hughes B, Chen P, et al. Changes in 25-hydroxy- and 1,25-dihydroxyvitamin D during treatment with teriparatide [abstract no. M424]. J Bone Miner Res 2007; 22 Suppl. 1: S210Google Scholar
  25. 25.
    Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 2004 Jul; 89(7): 3332–6PubMedCrossRefGoogle Scholar
  26. 26.
    Lindsay R, Cosman F, Zhou H, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006; 21(3): 366–73PubMedCrossRefGoogle Scholar
  27. 27.
    Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 2006 Jun; 21(6): 855–64PubMedCrossRefGoogle Scholar
  28. 28.
    Hurley M, Yao W, Lane NE. Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). Osteoporos Int 2005 Dec; 16(12): 2080–4PubMedCrossRefGoogle Scholar
  29. 29.
    Lindsay R, Cosman F, Zhou H, et al. Prior alendronate treatment does not inhibit the early stimulation of osteoblast activity in response to teriparatide. J Bone Miner Res 2007; 22 Suppl. 1: 124Google Scholar
  30. 30.
    Li J, Burr DB, Stepan JJ, et al. Teriparatide improves bone microarchitecture in postmenopausal women previously treated with alendronate [abstract no. 1095]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: S28Google Scholar
  31. 31.
    Dobnig H, Stepan JJ, Burr DB, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate [abstract no. 1093]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: S28Google Scholar
  32. 32.
    Jobke B, Muche B, Burghardt AJ, et al. Teriparatide administration following antiresorptive therapy (BBB-study): changes in 3D microarchitecture, mineralization and remodeling at the iliac crest after 6 months [abstract no. 419]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: 127Google Scholar
  33. 33.
    Keaveny TM, Donley DW, Hoffmann PF, et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007 Jan; 22(1): 149–57PubMedCrossRefGoogle Scholar
  34. 34.
    McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass [published erratum appears in Arch Intern Med 2005 Oct 10; 165 (18): 2120]. Arch Intern Med 2005 Aug 8; 165(15): 1762–8PubMedCrossRefGoogle Scholar
  35. 35.
    Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18(11): 1932–41PubMedCrossRefGoogle Scholar
  36. 36.
    Paschalis EP, Glass EV, Donley DW, et al. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab 2005 Aug; 90(8): 4644–9PubMedCrossRefGoogle Scholar
  37. 37.
    Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005 Jul; 20(7): 1244–53PubMedCrossRefGoogle Scholar
  38. 38.
    Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005 Jul; 90(7): 3970–7PubMedCrossRefGoogle Scholar
  39. 39.
    Vahle JL, Zuehlke U, Schmidt A, et al. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques following long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res 2008 Dec; 23(12): 2033–9PubMedCrossRefGoogle Scholar
  40. 40.
    Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2002/21-318_FORTEO_BioPharmr.pdf [Accessed 2008 Apr 14]
  41. 41.
    Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998 Oct 15; 102(8): 1627–33PubMedCrossRefGoogle Scholar
  42. 42.
    Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005 Aug 11; 353(6): 566–75PubMedCrossRefGoogle Scholar
  43. 43.
    Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001 May; 16(5): 925–31PubMedCrossRefGoogle Scholar
  44. 44.
    Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006 Aug; 91(8): 2882–7PubMedCrossRefGoogle Scholar
  45. 45.
    Lane NE, Sanchez S, Modin GW, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000 May; 15(5): 944–51PubMedCrossRefGoogle Scholar
  46. 46.
    Kung AW, Pasion EG, Sofiyan M, et al. A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin 2006 May; 22(5): 929–37PubMedCrossRefGoogle Scholar
  47. 47.
    Hwang JS, Tu ST, Yang TS, et al. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006; 17(3): 373–8Google Scholar
  48. 48.
    Genant HK, Halse J, Briney WG, et al. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 2005 Jul; 21(7): 1027–34PubMedCrossRefGoogle Scholar
  49. 49.
    Miller PD, Schwartz EN, Chen P, et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 2007 Jan; 18(1): 59–68PubMedCrossRefGoogle Scholar
  50. 50.
    Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005 Sep; 20(9): 1507–13PubMedCrossRefGoogle Scholar
  51. 51.
    Marcus R, Wang O, Satterwhite J, et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003 Jan; 18(1): 18–23PubMedCrossRefGoogle Scholar
  52. 52.
    Genant HK, Siris E, Crans GG, et al. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone 2005; 37(2): 170–4PubMedCrossRefGoogle Scholar
  53. 53.
    Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18(3): 539–43PubMedCrossRefGoogle Scholar
  54. 54.
    Boonen S, Marin F, Meilstrom D, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006 May; 54(5): 782–9PubMedCrossRefGoogle Scholar
  55. 55.
    Delmas PD, Licata AA, Reginster JY, et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 2006 Aug; 39(2): 237–43PubMedCrossRefGoogle Scholar
  56. 56.
    Gallagher JC, Genant HK, Crans GG, et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005 Mar; 90(3): 1583–7PubMedCrossRefGoogle Scholar
  57. 57.
    Adami S, Martin JS, Munoz-Torres M, et al. Effect of raloxifene after recombinant teriparatide [hPTH (1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 2008 Jan; 19(1): 87–94PubMedCrossRefGoogle Scholar
  58. 58.
    Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008 Mar; 93(3): 852–60PubMedCrossRefGoogle Scholar
  59. 59.
    Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008 May 27; 23(10): 1591–600PubMedCrossRefGoogle Scholar
  60. 60.
    Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004 Oct 11; 164(18): 2024–30PubMedCrossRefGoogle Scholar
  61. 61.
    Minne H, Audran M, Simoes ME, et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin 2008 Oct 4Google Scholar
  62. 62.
    Eastell R, Hadji P, Farrerons J, et al. Comparison of 3 sequential treatment regimens of teriparatide: final results from the EUROFORS study [abstract no. 1265]. J Bone Miner Res 2006 Sep; 21 Suppl. 1: 70Google Scholar
  63. 63.
    Uusi-Rasi K, Semanick LM, Zanchetta JR, et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005; 36(6): 948–58PubMedCrossRefGoogle Scholar
  64. 64.
    Chen P, Miller PD, Delmas PD, et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006 Nov; 21(11): 1785–90PubMedCrossRefGoogle Scholar
  65. 65.
    Cosman F, Wermers RA, Recknor C, et al. Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate [abstract no. O423]. J Bone Miner Res 2007; 22 Suppl. 1: 89Google Scholar
  66. 66.
    Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005 Jun; 20(6): 962–70PubMedCrossRefGoogle Scholar
  67. 67.
    Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005 May; 16(5): 510–6PubMedCrossRefGoogle Scholar
  68. 68.
    Adachi JD, Hanley DA, Lorraine JK, et al. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther 2007 Sep; 29(9): 2055–67PubMedCrossRefGoogle Scholar
  69. 69.
    Briot K, Ravaud P, Liu-Leage S, et al. Improvement of the persistence with teriparatide in postmenopausal osteoporosis: the French experience of an education program [abstract no. WG36]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: 508Google Scholar
  70. 70.
    Arden NK, Earl S, Fisher DJ, et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 2006; 17(11): 1626–9PubMedCrossRefGoogle Scholar
  71. 71.
    Fraenkel L, Gulanski B, Wittink D. Patient willingness to take teriparatide. Patient Educ Couns 2007; 65(2): 237–44PubMedCrossRefGoogle Scholar
  72. 72.
    Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006; 166(11): 1209–17PubMedCrossRefGoogle Scholar
  73. 73.
    Lundkvist J, Johnell O, Cooper C, et al. Economic evaluation of parathyroid hormone in the treatment of osteoporosis in postmenopausal women. Osteoporos Int 2006 Feb 1; 17(2): 201–11PubMedCrossRefGoogle Scholar
  74. 74.
    Pfister AK, Welch CA, Lester MD, et al. Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 2006 Feb; 99(2): 123–31PubMedCrossRefGoogle Scholar
  75. 75.
    Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, rise-dronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9(22): 1–160PubMedGoogle Scholar
  76. 76.
    National Institute for Clinical Excellence. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptors modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (technology appraisal 87) [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA087guidance.pdf [Accessed 2008 Jul 3]
  77. 77.
    Harper KD, Krege JH, Marcus R, et al. Comments on initial experience with teriparatide in the United States [letter]. Curr Med Res Opin 2006; 22(10): 1927PubMedCrossRefGoogle Scholar
  78. 78.
    Anastasilakis A, Goulis DG, Koukoulis G, et al. Acute and chronic effect of teriparatide on glucose metabolism in women with established osteoporosis. Exp Clin Endocrinol Diabetes 2007 Feb; 115(2): 108–11PubMedCrossRefGoogle Scholar
  79. 79.
    Sipos A, See K, Rohe M, et al. Antibody response to teriparatide 20μg: Treatment and follow-up [abstract no. SAT0338]. 2007 Annual European Congress of Rheumatology 2007 Jun 13, 85Google Scholar
  80. 80.
    MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008 Feb 5; 148(3): 197–213PubMedGoogle Scholar
  81. 81.
    Girotra M, Rubin RR, Bilezikian JP. Anabolic agents for osteoporosis: what is their likely place in therapy? Treatments in Endocrinology 2006; 5(6): 347–58PubMedCrossRefGoogle Scholar
  82. 82.
    Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006 May 30; 13(3): 340–67; quiz 368-9CrossRefGoogle Scholar
  83. 83.
    National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis [online]. Available from URL: http://www.nof.org/professionals/Clinicians_Guide.htm [Accessed 2008 Jul 21]
  84. 84.
    Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 149(6): 404–15PubMedGoogle Scholar
  85. 85.
    Brown JP, Josse RG, for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002 Nov 12; 167 Suppl. 10: S1–34Google Scholar
  86. 86.
    National Institute for Health and Clinical Excellence. Osteoporosis — secondary prevention including strontium ranelate: appraisal consultation document (March 2008) [online]. Available from URL: http://www.nice.org.uk/guidance/index.jsp?action=article&o=40252 [Accessed 2008 Jul 7]
  87. 87.
    Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008 Apr; 19 (4)Google Scholar
  88. 88.
    National Health Service: Clinical Knowledge Summaries. Osteoporosis — treatment [online]. Available from URL: http://www.prodigy.nhs.uk/osteoporosis_treatment [Accessed 2008 Jul 7]
  89. 89.
    Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349(13): 1207–15PubMedCrossRefGoogle Scholar
  90. 90.
    Tashjian Jr AH, Gagel RF. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006; 21(3): 354–65PubMedCrossRefGoogle Scholar
  91. 91.
    Graeff C, Gluer CC, Borggrefe I, et al. Effects of 2 years of teriparatide treatment on bone strength assessed by high resolution CT based finite element analysis of human vertebrae in vivo: results from the EUROFORS study. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: 323Google Scholar
  92. 92.
    Bodenner D, Redman C, Riggs A. Teriparatide in the management of osteoporosis. Clin Interv Aging 2007; 2(4): 499–507PubMedGoogle Scholar
  93. 93.
    Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004 May; 19(5): 745–51PubMedCrossRefGoogle Scholar
  94. 94.
    Rajzbaum G, Jakob F, Karras D, et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008 Feb; 24(2): 377–84PubMedCrossRefGoogle Scholar
  95. 95.
    Miller PD, Silverman SL, Gold DL, et al. Rationale, objectives and design of the direct analysis of nonvertebral fracture in the community experience (DANCE) study. Osteoporos Int 2006; 17: 85–90PubMedCrossRefGoogle Scholar
  96. 96.
    Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications. Drugs Aging 2007; 24(1): 37-55PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Stephanie K. A. Blick
    • 1
    • 2
  • Sohita Dhillon
    • 1
    • 2
  • Susan J. Keam
    • 1
    • 2
  1. 1.Wolters Kluwer Health | AdisMairangi Bay, North Shore 0754, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations